Lv71
4650 积分 2023-05-29 加入
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes
1个月前
已完结
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial
1个月前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
1个月前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
2个月前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
2个月前
已关闭
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2个月前
已完结
皖公网安备34019202002308
